MRD Monitoring May Help Redefine Long-Term Goals in Myeloma Therapy

Measuring minimal residual disease (MRD) is a growing area of interest in the treatment landscape of multiple myeloma (MM), an incurable hematologic malignancy characterized by increasingly poorer responses as patients progress through therapy. MRD testing can be a useful tool and give valuable insights into disease status, helping guide more personalized treatment strategies. At the 2025 American Society of Clinical Oncology Annual Meeting, experts discussed the current landscape of MRD testing and shared valuable insights about how to measure MRD and how to use it to determine optimal treatment intensity and durations, thereby guiding treatment decision-making.